Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma

We report a patient with metastatic urothelial carcinoma treated with enfortumab vedotin who developed erythematous, scaly papules and plaques on his torso and extremities with corresponding histologic features of vacuolar interface dermatitis and maturation disarray of keratinocytes. He was successfully treated with topical corticosteroids. Cutaneous toxicity appears to be a common adverse reaction in this growing class of antibody-drug conjugates.
Source: Dermatology Online Journal - Category: Dermatology Source Type: research